Cargando…

Combined C-Reactive Protein and Novel Inflammatory Parameters as a Predictor in Cancer—What Can We Learn from the Hematological Experience?

The acute phase reaction is a systemic response to acute or chronic inflammation. The serum level of C-reactive protein (CRP) is the only acute phase biomarker widely used in routine clinical practice, including its uses for prognostics and therapy monitoring in cancer patients. Although Interleukin...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bruserud, Øystein, Aarstad, Helene Hersvik, Tvedt, Tor Henrik Anderson
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7409204/ https://www.ncbi.nlm.nih.gov/pubmed/32707721 http://dx.doi.org/10.3390/cancers12071966

Ejemplares similares

The Acute Phase Reaction and Its Prognostic Impact in Patients with Head and Neck Squamous Cell Carcinoma: Single Biomarkers Including C-Reactive Protein Versus Biomarker Profiles
por: Aarstad, Helene Hersvik, et al.
Publicado: (2020)

The Biological Context of C-Reactive Protein as a Prognostic Marker in Renal Cell Carcinoma: Studies on the Acute Phase Cytokine Profile
por: Aarstad, Helene Hersvik, et al.
Publicado: (2020)

Cytokine Release Syndrome in the Immunotherapy of Hematological Malignancies: The Biology behind and Possible Clinical Consequences
por: Tvedt, Tor Henrik Anderson, et al.
Publicado: (2021)

Serum levels of the IL-6 family of cytokines predict prognosis in renal cell carcinoma (RCC)
por: Gudbrandsdottir, Gigja, et al.
Publicado: (2020)

Interleukin-6 in Allogeneic Stem Cell Transplantation: Its Possible Importance for Immunoregulation and As a Therapeutic Target
por: Tvedt, Tor Henrik Anderson, et al.
Publicado: (2017)

The Complexity of Targeting PI3K-Akt-mTOR Signalling in Human Acute Myeloid Leukaemia: The Importance of Leukemic Cell Heterogeneity, Neighbouring Mesenchymal Stem Cells and Immunocompetent Cells
por: Brenner, Annette K., et al.
Publicado: (2016)

Immunological Heterogeneity of Healthy Peripheral Blood Stem Cell Donors—Effects of Granulocyte Colony-Stimulating Factor on Inflammatory Responses
por: Tvedt, Tor Henrik Anderson, et al.
Publicado: (2018)

Clonal Heterogeneity Reflected by PI3K-AKT-mTOR Signaling in Human Acute Myeloid Leukemia Cells and Its Association with Adverse Prognosis
por: Nepstad, Ina, et al.
Publicado: (2018)

Immunomodulatory Drugs Alter the Metabolism and the Extracellular Release of Soluble Mediators by Normal Monocytes
por: Rundgren, Ida Marie, et al.
Publicado: (2020)

Therapeutic Use of Valproic Acid and All-Trans Retinoic Acid in Acute Myeloid Leukemia—Literature Review and Discussion of Possible Use in Relapse after Allogeneic Stem Cell Transplantation
por: Bruserud, Øystein, et al.
Publicado: (2021)

Preconditioning Serum Levels of Endothelial Cell-Derived Molecules and the Risk of Posttransplant Complications in Patients Treated with Allogeneic Stem Cell Transplantation
por: Lindås, Roald, et al.
Publicado: (2014)

The Constitutive Extracellular Protein Release by Acute Myeloid Leukemia Cells—A Proteomic Study of Patient Heterogeneity and Its Modulation by Mesenchymal Stromal Cells
por: Aasebø, Elise, et al.
Publicado: (2021)

Combination of Intensive Chemotherapy and Anticancer Vaccines in the Treatment of Human Malignancies: The Hematological Experience
por: Liseth, Knut, et al.
Publicado: (2010)

Necrotizing Bacterial Myositis as the Initial Presentation of Severe Aplastic Anaemia
por: Rørvik, Synne Dragesund, et al.
Publicado: (2021)

IL-6 Responsiveness of CD4(+) and CD8(+) T Cells after Allogeneic Stem Cell Transplantation Differs between Patients and Is Associated with Previous Acute Graft versus Host Disease and Pretransplant Antithymocyte Globulin Therapy
por: Tvedt, Tor Henrik Anderson, et al.
Publicado: (2022)

In Vitro-Stimulated IL-6 Monocyte Secretion and In Vivo Peripheral Blood T Lymphocyte Activation Uniquely Predicted 15-Year Survival in Patients with Head and Neck Squamous Cell Carcinoma
por: Aarstad, Helene Hersvik, et al.
Publicado: (2015)

Targeting Cellular Metabolism in Acute Myeloid Leukemia and the Role of Patient Heterogeneity
por: Grønningsæter, Ida Sofie, et al.
Publicado: (2020)

Spontaneous Splenic Artery Rupture as the First Symptom of Systemic Amyloidosis
por: Bruserud, Øyvind, et al.
Publicado: (2021)

Pretransplant Levels of CRP and Interleukin-6 Family Cytokines; Effects on Outcome after Allogeneic Stem Cell Transplantation
por: Tvedt, Tor Henrik, et al.
Publicado: (2016)

Effects of the Autophagy-Inhibiting Agent Chloroquine on Acute Myeloid Leukemia Cells; Characterization of Patient Heterogeneity
por: Grønningsæter, Ida Sofie, et al.
Publicado: (2021)

Vacuolar ATPase Is a Possible Therapeutic Target in Acute Myeloid Leukemia: Focus on Patient Heterogeneity and Treatment Toxicity
por: Bartaula-Brevik, Sushma, et al.
Publicado: (2023)

Inflammatory Injury to the Neonatal Brain – What Can We Do?
por: Ofek-Shlomai, Noa, et al.
Publicado: (2014)

Future Perspectives: Therapeutic Targeting of Notch Signalling May Become a Strategy in Patients Receiving Stem Cell Transplantation for Hematologic Malignancies
por: Ersvaer, Elisabeth, et al.
Publicado: (2011)

Bone marrow abnormalities detected by magnetic resonance imaging as initial sign of hematologic malignancies
por: Grønningsæter, Ida Sofie, et al.
Publicado: (2018)

Hematopoiesis, Inflammation and Aging—The Biological Background and Clinical Impact of Anemia and Increased C-Reactive Protein Levels on Elderly Individuals
por: Bruserud, Øystein, et al.
Publicado: (2022)

A Pilot Study of Circulating Monocyte Subsets in Patients Treated with Stem Cell Transplantation for High-Risk Hematological Malignancies
por: Rundgren, Ida Marie, et al.
Publicado: (2020)

Can hematologic parameters predict treatment of ectopic pregnancy?
por: Akkaya, Hatice, et al.
Publicado: (2017)

What Can We Demonstrate?
por: Mills, G. A.
Publicado: (1896)

Reversal Agents: What We Have and What We Can Expect
por: Ruff, Christian T.
Publicado: (2018)

Enhancer RNA: What we know and what we can achieve
por: Han, Zhenzhen, et al.
Publicado: (2022)

What we can and what we cannot see with extracellular multielectrodes
por: Chintaluri, Chaitanya, et al.
Publicado: (2021)

The origin of life: what we know, what we can know and what we will never know
por: Pross, Addy, et al.
Publicado: (2013)

Routine Hematological Parameters May Be Predictors of COVID-19 Severity
por: Szklanna, Paulina B., et al.
Publicado: (2021)

Hematological Parameter as Predictor Mortality in Acute Myocardial Infarction Patients
por: Firani, Novi Khila, et al.
Publicado: (2022)

Health insurance system for hematologic diseases: what should we do?
por: Jang, Moon Ju, et al.
Publicado: (2011)

COVID-19 and Hematology—What Do We Know So Far?
por: Khandait, Harshwardhan, et al.
Publicado: (2020)

WHAT HAVE WE EXPERIENCED WITH COVID-19 IN PATIENTS WITH HEMATOLOGICAL DISORDERS?
por: ERDEM, Simge, et al.
Publicado: (2021)

Diagnostic significance of C-reactive protein and hematological parameters in acute toxoplasmosis
por: Sandri, Vanessa, et al.
Publicado: (2020)

Hematological and Inflammatory Parameters to Predict the Prognosis in COVID-19
por: Keski, Hakan
Publicado: (2021)

Quasicrystals: What do we know? What do we want to know? What can we know?
por: Steurer, Walter
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_feihnfvtp56197kbmop75sf3h3